Logo

Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA TRAVERSE OLE Study for Asthma

Share this

Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA TRAVERSE OLE Study for Asthma

Shots:

  • The P-III OLE study involves assessing of Dupixent (300mg) + SOC in 2-282 adults/ adolescents with mod.-to-sev. asthma prior participated in a controlled Dupixent clinical trial- including the pivotal P-IIb DRI (24wks.) and P-III QUEST (52wks.) trials in patients with mod.-to-sev. asthma and the P-III VENTURE (24wks.) trial in patients with severe OCS-dependent asthma
  • The P-III OLE study results demonstrated the safety & efficacy profile observed in previous Dupixent trials were maintained for up to 3yrs. i.e-  improvement in lung function by 13-22% @96wks.- patients maintained a low rate of severe asthma attacks- AE rates (76-88%) and will be presented at 2020 ERS International Congress
  • Dupixent is a mAb inhibiting the signaling of the IL-4 & IL-13 proteins and is the only biologic  to demonstrate sustained improvements in lung function and asthma exacerbations across a broad patient population with type 2 inflammation

­ Ref: Sanofi | Image: News Medical

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions